REVIEW PAPER
Tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome in HIV: immunological review of manifestation and immunopathogenesis
1
Infectious Disease Immunology, Dr. B.R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi, India
2
Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
3
Product Development Cell-1, National Institute of Immunology, New Delhi, India
4
Jamia Hamdard Institute of Molecular Medicine, Hamdard University, Delhi, India
Submission date: 2019-05-28
Final revision date: 2019-07-31
Acceptance date: 2019-10-09
Publication date: 2020-06-28
HIV & AIDS Review 2020;19(2):67-73
KEYWORDS
TOPICS
epidemiology - population studiessocio-medical aspects of HIV and AIDSeducational aspects of HIV and AIDS
ABSTRACT
Tuberculosis (TB) is the most common opportunistic infection that makes human immunodeficiency virus (HIV) infection more complicated. TB-immune reconstitution inflammatory syndrome (TB-IRIS) mainly refers to an excessive immune response among HIV-infected patients. In HIV-infected patients, IRIS occurs after initiation of antiretroviral therapy (ART), irrespective of increased CD4 count and effective suppression of HIV viremia; IRIS may occur at any stage in the progression of immunodeficiency and manifests with weakened immune system. IRIS is associated with various inflammatory processes as the outcome of immunological reaction against a variety of opportunistic infections (OIs). Currently, there is no reliable biological marker available for diagnosis of TB-IRIS. In accordance with current clinical case definition, deterioration of clinical and radiological symptoms of pre-existing TB infection in HIV patients is called “paradoxical TB-IRIS”. The appearance of a previously undiagnosed or new TB infection during ART treatment is called “unmasking TB-IRIS”. IRIS is a challenging complication for researchers and medical practitioners, as the incidence of IRIS is between 3-40% in patients initiated on ART. The variation in incidence probably reflects the differences in case definitions, patients’ population studied, and individual resource-limited settings. The immune pathogenesis of IRIS is poorly understood, and epidemiology partially defined. The complication for clinicians remains challenging in terms of diagnosis and treatment as well as patients’ suffering, even though, the mortality is typically low.
REFERENCES (47)
1.
Walker NF, Stek C, Wasserman S, Wilkinson RJ, Meintjes G. The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research. Curr Opin HIV AIDS 2018; 13: 512-521.
2.
Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: A prospective cohort study. PLoS Med 2010; 7: 1-14.
3.
Ravimohan S, Tamuhla N, Steenhoff AP, et al. Therapy: a prospective observational cohort study. Lancet Infect Dis 2016; 15: 429-438.
4.
Wilson EM, Sereti I. Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunol Rev 2014; 254: 343-354.
5.
Lanzafame M, Vento S. Tuberculosis-immune reconstitution inflammatory syndrome. J Clin Tuberc Other Mycobact Dis 2016; 3: 6-9.
6.
French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615-1627.
7.
Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57: 167-170.
8.
Colebunders R, John L, Huyst V, Kambugu A, Scano F, Lynen L. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis 2006; 10: 946-953.
9.
Grant PM, Komarow L, Lederman MM, et al. Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during actg a5164. J Infect Dis 2012; 206: 1715-1723.
10.
Sharma SK, Soneja M. HIV & immune reconstitution inflammatory syndrome (IRIS). Indian J Med Res 2011; 134: 866-877.
11.
Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39: 1709-1712.
12.
Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Incidence and lethality of immune reconstitution disease in HIV-infected patients starting antiretroviral therapy: systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 251-261.
13.
Sharma SK, Karmakar S, Vashishtha R, et al. Clinical characteristics of tuberculosis-associated immune reconstitution inflammatory syndrome in North Indian population of HIV/AIDS patients receiving HAART. Clin Dev Immunol 2011; 2011: 239021.
14.
Sharma SK, Dhooria S, Barwad P, Kadhiravan T, Ranjan S. A study of TB-associated immune reconstitution inflammatory syndrome using the consensus case-definition. Indian J Med Res 2010; 131: 805-808.
15.
Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19: 399-406.
16.
Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with aids. Am J Respir Crit Care Med 1998; 158: 157-161.
17.
Burman W, Weis S, Vernon A, et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 2007; 11: 1282-1289.
18.
Jevtović DJ, Salemović D, Ranin J, Pešić I, Žerjav S, Djurković-Djaković O. The prevalence and risk immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2005; 6: 140-143.
19.
Breen RAM, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 2004; 59: 704-707.
20.
Lawn SD, Bekker LG MR. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5: 361-373.
21.
Price P, Morahan G, Huang D, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002; 16: 2043-2047.
22.
Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42: 418-427.
23.
Bruchfeld J, Correia-Neves M, Käallenius G. Tuberculosis and HIV coinfection. Cold Spring Harb Perspect Med 2015; 5: a017871.
24.
Toossi Z, Johnson JL, Kanost RA, et al. Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. J Acquir Immune Defic Syndr 2001; 28: 1-8.
25.
Goletti D, Weisman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV Replication. J Immunol 1996; 157: 1271-1278.
26.
Naidoo K, Naidoo K, Padayatchi N, Abdool Karim Q. HIV-associated tuberculosis. Clin Dev Immunol 2011; 2011: 585919.
27.
Padmapriyadarsini C, Narendran G, Swaminathan S. Diagnosis & treatment of tuberculosis in HIV co-infected patients. Indian J Med Res 2011; 134: 850-865.
28.
Kwan C, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev 2011; 24: 351-376.
29.
Diedrich CR, Flynn JAL. HIV-1/Mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis? Infect Immun 2011; 79: 1407-1417.
30.
Andrews CA, Koup RA. The immunopathology of HIV infection. J Antimicrob Chemother 1996; 37 Suppl B: 13-25.
31.
Kulane A, Ahlberg BM, Berggren I. “It is more than the issue of taking tablets”: the interplay between migration policies and TB control in Sweden. Health Policy (New York) 2010; 97: 26-31.
32.
Pawlowski A, Jansson M, Sköld M, Rottenberg ME, Källenius G. Cornea transplant at Parma between 1983 and 1990. New Trends Ophthalmol 1991; 6: 343-347.
33.
Arbex MA, Varella M de CL, Mello HR de SFAF de. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: First-line drugs. J Bras Pneumol 2010; 36: 626-640.
34.
French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009; 48: 101-107.
35.
Seddiki N, Sasson SC, Santner-Nanan B, et al. Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease. Eur J Immunol 2009; 39: 391-403.
36.
Goicoechea M, Smith DM, Liu L, et al. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 2006; 194: 29-37.
37.
Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999; 103: 1391-1398.
38.
Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116.
39.
Stone JD, Cochran JR, Stern LJ. T-cell activation by soluble MHC oligomers can be described by a two-parameter binding model. Biophys J 2001; 81: 2547-2557.
40.
Shankar EM, Vignesh R, Velu V, et al. Does CD4+CD25+foxp3+ cell (Treg) and IL-10 profile determine susceptibility to immune reconstitution inflammatory syndrome (IRIS) in HIV disease? J Inflamm (Lond) 2008; 5: 2.
41.
Swaminathan S, Padmapriyadarsini C, Narendran G, Thomas BE, Anand S, Rajyalakshmi A. Immune reconstitution syndrome following initiation of antiretroviral therapy in a patient with HIV infection and multidrug-resistant tuberculosis. Indian J Chest Dis Allied Sci 2005; 47: 299-304.
42.
Narendran G, Swaminathan S, Sathish S, Rajasekaran S. Immune reconstitution syndrome in a child with TB and HIV. Indian J Pediatr 2006; 73: 627-629.
43.
Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of Treg-mediated T cell suppression. Front Immunol 2012; 3: 51.
44.
Zheng Y, Manzotti CN, Liu M, Burke F, Mead KI, Sansom DM. CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J Immunol 2004; 172: 2778-2784.
45.
Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2: 116-126.
46.
Sansom DM, Manzotti CN, Zheng Y. What’s the difference between CD80 and CD86? Trends Immunol 2003; 24: 314-319.
47.
Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24: 2381-2390.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
